Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 222

Results For "IMI"

3813 News Found

Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg
Drug Approval | February 18, 2023

Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg

Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)


Lupin receives EIR from USFDA for injectable facility in Nagpur
News | February 18, 2023

Lupin receives EIR from USFDA for injectable facility in Nagpur

The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022


Briefs: Piramal Pharma, Alembic Pharmaceuticals
News | February 17, 2023

Briefs: Piramal Pharma, Alembic Pharmaceuticals

USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA


AstraZeneca Pharma India receives no objection for Durvalumab
Drug Approval | February 17, 2023

AstraZeneca Pharma India receives no objection for Durvalumab

Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer


Biocon Q3 FY23 revenue up 36%
News | February 17, 2023

Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses


Shilpa Medicare Unit VI Bengaluru facility registered with Ministry of Health, UAE
News | February 17, 2023

Shilpa Medicare Unit VI Bengaluru facility registered with Ministry of Health, UAE

This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization


Zydus receives tentative approval from USFDA for Bosentan tablets for oral suspension
Drug Approval | February 16, 2023

Zydus receives tentative approval from USFDA for Bosentan tablets for oral suspension

Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022)


Zydus receives tentative approval from the USFDA for Canagliflozin tablets
Drug Approval | February 16, 2023

Zydus receives tentative approval from the USFDA for Canagliflozin tablets

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya


Panacea Biotec posts Q3 FY2023 net profit at Rs.19.37 crores
News | February 16, 2023

Panacea Biotec posts Q3 FY2023 net profit at Rs.19.37 crores

The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.


Wockhardt registers Q3 FY23 consolidated loss at Rs. 96 Cr
News | February 15, 2023

Wockhardt registers Q3 FY23 consolidated loss at Rs. 96 Cr

The company has reported total income of Rs. 701 crores during the period ended December 31, 2022